AI Terminal
DIACEUTICS PLC
Report Publication Announcement • Apr 28, 2022
7596_agm-r_2022-04-28_b7602623-138a-4469-a4a6-f4767a5226ae.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 7347J
Diaceutics PLC
28 April 2022
28 April 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Notice of AGM and Posting of Annual Report
Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company announces that it will today post its Annual Report for the year ended 31 December 2021 to shareholders together with the Notice of the 2022 Annual General Meeting ("AGM").
The Company will hold its AGM on Thursday 26 May 2022 at 10.30am at First Floor, Building Two, Dataworks at Kings Hall Health and Wellbeing Park, Belfast, County Antrim BT9 6GW.
The Annual Report and Notice of AGM will also be available shortly on the Company's website at www.diaceutics.com .
Enquiries:
| Diaceutics PLC | |
| Nick Roberts, Chief Financial Officer | Via Alma PR |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Stewart Wallace | |
| Nick Adams | |
| Alma PR | Tel: +44(0)20 3405 0205 |
| Caroline Forde | [email protected] |
| Kieran Breheny | |
| Matthew Young |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NOABBGDSRDDDGDI